Calliditas Therapeutics AB revenue breakdown overview

Calliditas Therapeutics AB revenue for the last year amounted to 116.25 M USD, the most of which — 102.43 M USD — came from its highest performing source at the moment, Therapeutics for Renal Disease Immunoglobulin, the year earlier bringing 37.11 M USD. The greatest contribution to the revenue figure was made by United States — last year it brought Calliditas Therapeutics AB 101.34 M USD, and the year before that — 36.78 M USD.